Sanofi and Regeneron score early access for dupilumab in UK; Sanders skewers Sanofi on Zika vaccine
→ Sanofi and Regeneron have scored boasting rights for an early stamp of approval on their closely-watched eczema drug dupilumab. With a US approval looming …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
